Skip to Content

Heart Research

For more information about these heart research studies, call 320-251-2700, ext. 57584 or e-mail Heart Research.

CentraCare Heart & Vascular Center takes an active role in heart research. Our goal is to find better ways to prevent, diagnose and treat heart disease so you can live better and longer.

Why participate in heart research?

  • Early access to new drugs and treatments
  • Help others who have heart problems, both today and in the future
  • Play a role in the discovery of new drugs, treatments and cures

As one of Minnesota's largest heart hospitals, we are one of the few sites in the state with a department dedicated to heart research.

Current research studies

Prevention Studies

SPIRE-1: This study compares the effects of the study drug, bococizumab (also called PF 04950615), with a placebo to find out how effective and safe bococizumab is in reducing the risk of major cardiovascular events, (heart attacks, strokes, and hospitalization for chest pain), when added to other cholesterol treatments. Placement into SPIRE I is dependent on lipid panel lab results.

More information

Esperion Clear Harmony: ETC-1002 is an investigational drug being developed by Esperion Therapeutics, Inc. as an add on to treatment of hyperlipidemia in people at high cardiovascular risk. In this study, ETC-1002 or placebo will be taken along with the cholesterol-lowering medication(s) you have been prescribed by your regular doctor and are currently taking.

More information

Voyager-PAD: The purpose of this study is to find out about the safety and efficacy of rivaroxaban combined with aspirin in reducing the risk of major cardiovascular events (e.g., stroke or heart attack) after a person with vessel disease in their legs has had a revascularization procedure to improve blood flow.

More information

Re-Dual-PCI: The purpose of this research study is to compare the effectiveness and safety of two different study drug treatment groups in subjects with non-valvular atrial fibrillation who have undergone a PCI with a stent put in.

More information

Dal-Gene: The purpose of this study is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in subjects with a documented recent Acute Coronary Syndrome and the AA genotype at variant rs 1967309 in the ADCY9 gene.

More information

Harmony: The purpose of this study is to find out whether people taking albiglutide for diabetes have a higher or lower risk of developing cardiovascular complications (heart attack, stroke, or death from cardiovascular disease), than people who do not take albiglutide. Albiglutide is a medicine (given as a weekly injection) used to lower blood sugar levels in people with diabetes.

More information

Artemis: The purpose of this study is to learn more about how long patients take antiplatelet medications after hospital discharge and how this influences patients' long-term health and use of healthcare resources.

More information

Twilight: This study will look to determine the effectiveness and safety of ticagrelor alone, compared to ticagrelor plus aspirin in reducing clinically relevant bleeding among high-risk patients who have had a percutaneous intervention (a procedure done through the skin into an artery to open a blocked vessel in the heart), with at least one drug-eluting stent (a stent covered with medication that helps to control the rate of tissue growth at the stent site so as to prevent scars from forming) and in reducing ischemic adverse events (not enough oxygenated blood supply to a major organ, like the heart, brain, etc.) A patient is considered high-risk if they meet certain clinical and/or anatomic criteria.

More information

CIRT: The Cardiovascular Inflammation Reduction Trial (CIRT) looks at whether taking low-dose methotrexate reduces heart attacks, strokes or death in people with type 2 diabetes or metabolic syndrome who have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH).

More information

GLORIA-AF: This is a registry study for patients recently diagnosed with atrial fibrillation.

More information

Heart Failure Studies

Paragon: This study evaluates the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure (HF) hospitalizations in HF patients with preserved ejection fraction.

More information

CardioMems: The CardioMEMS HF System provides a method to measure pulmonary artery (PA) pressures by using a small wireless sensor (about the size of a paperclip) implanted into the pulmonary artery (a vessel close to your heart). Once implanted, the sensor communicates through radio frequency to an antenna contained in a pillow connected to an electronic unit and then transmits this valuable information to a secure website for your doctor to review. You will be able to take these PA pressure measurements yourself at home. In addition to these home readings, your PA pressures can also be obtained in the physician’s office, clinic, or hospital. Your doctor can access the secure website to view your measurements allowing him/her to make earlier treatment changes (usually changes in medications) to manage your heart failure remotely.

More information

Device Studies

UNTOUCHED: The primary purpose of this study is to evaluate and report on Boston Scientific’s S-ICD System

More information

WRAP-IT: This study will evaluate the ability of the TYRX envelope to reduce major CIED infections through 12-months post-procedure following CIED generator replacement, upgrade, revision, or de novo CRT-D implant.

More information

Enable-MRI: The ENABLE MRI (Magnetic Resonance Imaging) Study will enroll subjects either eligible for implantation with an Implantable Cardioverter Defibrillator (ICD) or with an ICD already implanted. Only ICD models and associated leads and accessories belonging to Boston Scientific’s ImageReady MR Conditional Defibrillation System will be used.

More information

The CentraCare Heart & Vascular Center Research Department undergoes rigorous review from the St. Cloud Hospital Institutional Review Board (IRB). The purpose of the IRB is to protect the rights and safety of people who volunteer to take part in research studies. To contact the IRB, call 320-255-5785.